Background: Infertile obese women with polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting women and characterized by hyperandrogenism, chronic anovulation with either oligomenorrhea or amenorrhea and hyperandrogenism, and its morbidity may include hyperinsulinemia, insulin resistance. Lipolax was used to enhance the ovulation response especially when beginning the intra cytoplasmic sperm injection (ICSI) protocol. This study aimed to enhance the sexual hormones, lipid profile, ovulation response and pregnancy outcome in infertile obese PCOS women's treated with Lipolax drug (fenofibrate) before undergoing to ICSI. Setting: This study was conducted in International Islamic Center for Population Studies and Research-Assisted Reproduction Unit, Al-Azhar University during the period between 2009 and 2011. Patients and Methods:  A total number of 75 infertile patients with obese PCOS were randomized to receive oral Lipolax (fenofibrate) for three months before undergoing to ICSI. For each patient FBS and Hb, hormonal profile included FSH, LH, FSH/LH ratio, E₂, PRL and lipid profile evaluation were performed at baseline and after 3 months of treatment. Results: There was a significant decrease in the FBS, in cases treated with Lipolax when compared with control or obese PCOS, no significant differences were noticed in the level of Hb% in both groups. Total lipids, triglycerides and total cholesterol decreased significantly compared with obese PCOS group. Significant decrease was also observed in respect to LDL in cases of Lipolax treated group than cases of obese PCOS, significant increase in the level of HDL was recorded. A significant enhance was detected in increase FSH hormone level and decrease LH, FSH/LH ratio and E₂ hormonal level after Lipolax treatment, no difference was observed in prolactin hormonal profile. Observed improvement was detected in the number of HMG ampoules, mature oocytes, and number of grade A embryos and also in pregnancy outcome. Conclusion: Lipolax (lowering cholesterol agent) improving the response in obese PCOS women undergoing ICSI, by enhance their resistance sensitivity in transadipose tissue leads to improve the function of gonads and sexual hormones and lipids profile which leads to decreased total cost of ICSI by lowering the number of stimulation ampoules and increase mature collected oocytes and finally the percent of successful pregnancy rate.